GB0321538D0 - Therapeutically useful compounds - Google Patents

Therapeutically useful compounds

Info

Publication number
GB0321538D0
GB0321538D0 GBGB0321538.1A GB0321538A GB0321538D0 GB 0321538 D0 GB0321538 D0 GB 0321538D0 GB 0321538 A GB0321538 A GB 0321538A GB 0321538 D0 GB0321538 D0 GB 0321538D0
Authority
GB
United Kingdom
Prior art keywords
alkyl
alkylaryl
cor
optionally substituted
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0321538.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0321538.1A priority Critical patent/GB0321538D0/en
Publication of GB0321538D0 publication Critical patent/GB0321538D0/en
Priority to MXPA06002458A priority patent/MXPA06002458A/es
Priority to CA2538315A priority patent/CA2538315C/en
Priority to AU2004272280A priority patent/AU2004272280C1/en
Priority to CN200480026229.7A priority patent/CN1849306B/zh
Priority to JP2006525794A priority patent/JP2007505081A/ja
Priority to EP08163972A priority patent/EP2042488B1/en
Priority to KR1020067005114A priority patent/KR20060120648A/ko
Priority to KR1020137014317A priority patent/KR20130079628A/ko
Priority to EP04765231A priority patent/EP1663970B1/en
Priority to AT08163972T priority patent/ATE502922T1/de
Priority to EP10176905A priority patent/EP2295408A1/en
Priority to ES04765231T priority patent/ES2314436T3/es
Priority to ES08163972T priority patent/ES2362954T3/es
Priority to DE602004031991T priority patent/DE602004031991D1/de
Priority to NZ545211A priority patent/NZ545211A/en
Priority to HR20080668T priority patent/HRP20080668T3/xx
Priority to HK06112572.5A priority patent/HK1092141B/en
Priority to PL04765231T priority patent/PL1663970T3/pl
Priority to US10/571,443 priority patent/US7601729B2/en
Priority to RU2006106850/04A priority patent/RU2370488C2/ru
Priority to PCT/EP2004/010319 priority patent/WO2005026120A1/en
Priority to KR1020127000264A priority patent/KR20120007566A/ko
Priority to NZ573479A priority patent/NZ573479A/en
Priority to DK04765231T priority patent/DK1663970T3/da
Priority to BRPI0413791-4A priority patent/BRPI0413791A/pt
Priority to DE602004017622T priority patent/DE602004017622D1/de
Priority to SI200431008T priority patent/SI1663970T1/sl
Priority to AT04765231T priority patent/ATE413384T1/de
Priority to PT04765231T priority patent/PT1663970E/pt
Priority to SG200805432-2A priority patent/SG145685A1/en
Priority to IL173305A priority patent/IL173305A/en
Priority to IS8268A priority patent/IS2622B/is
Priority to NO20060540A priority patent/NO20060540L/no
Priority to ZA200602070A priority patent/ZA200602070B/en
Priority to MA28873A priority patent/MA28039A1/fr
Priority to US12/266,767 priority patent/US8263602B2/en
Priority to RU2008146479/04A priority patent/RU2008146479A/ru
Priority to CY20091100090T priority patent/CY1109400T1/el
Priority to IS8843A priority patent/IS8843A/is
Priority to US12/551,892 priority patent/US8343986B2/en
Priority to JP2011132261A priority patent/JP2011231118A/ja
Priority to JP2012012663A priority patent/JP2012107031A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Soft Magnetic Materials (AREA)
  • Indole Compounds (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
GBGB0321538.1A 2003-09-13 2003-09-13 Therapeutically useful compounds Ceased GB0321538D0 (en)

Priority Applications (43)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds
SG200805432-2A SG145685A1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
RU2006106850/04A RU2370488C2 (ru) 2003-09-13 2004-09-10 Ингибиторы матриксных металлопротеиназ
PCT/EP2004/010319 WO2005026120A1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
AU2004272280A AU2004272280C1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
CN200480026229.7A CN1849306B (zh) 2003-09-13 2004-09-10 基质金属-蛋白酶抑制剂
JP2006525794A JP2007505081A (ja) 2003-09-13 2004-09-10 マトリックスメタロプロテイナーゼの阻害剤
EP08163972A EP2042488B1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
KR1020067005114A KR20060120648A (ko) 2003-09-13 2004-09-10 기질 금속단백분해효소 억제제
KR1020137014317A KR20130079628A (ko) 2003-09-13 2004-09-10 기질 금속단백분해효소 억제제
EP04765231A EP1663970B1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
AT08163972T ATE502922T1 (de) 2003-09-13 2004-09-10 Matrix-metalloproteinaseinhibitoren
EP10176905A EP2295408A1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
ES04765231T ES2314436T3 (es) 2003-09-13 2004-09-10 Inhibidores de las metaloproteinasas de matriz.
ES08163972T ES2362954T3 (es) 2003-09-13 2004-09-10 Inhibidores de metaloproteinasas de matriz.
DE602004031991T DE602004031991D1 (de) 2003-09-13 2004-09-10 Matrix-Metalloproteinaseinhibitoren
NZ545211A NZ545211A (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
HR20080668T HRP20080668T3 (hr) 2003-09-13 2004-09-10 Inhibitori matričnih metaloproteinaza
HK06112572.5A HK1092141B (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
NZ573479A NZ573479A (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
US10/571,443 US7601729B2 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
MXPA06002458A MXPA06002458A (es) 2003-09-13 2004-09-10 Inhibidores de metaloproteinasa matriz.
KR1020127000264A KR20120007566A (ko) 2003-09-13 2004-09-10 기질 금속단백분해효소 억제제
PL04765231T PL1663970T3 (pl) 2003-09-13 2004-09-10 Inhibitory metaloproteinaz macierzy
CA2538315A CA2538315C (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors
DK04765231T DK1663970T3 (da) 2003-09-13 2004-09-10 Matrixmetalloproteinaseinhibitorer
BRPI0413791-4A BRPI0413791A (pt) 2003-09-13 2004-09-10 composto, método para o tratamento de um indivìduo humano ou animal que sofre de, ou que é suscetìvel a um distúrbio auto-imune ou uma condição inflamatória, uso de um composto, composição farmacêutica, e, processo para a prearação de compostos
DE602004017622T DE602004017622D1 (de) 2003-09-13 2004-09-10 Matrixmetalloproteinaseinhibitoren
SI200431008T SI1663970T1 (sl) 2003-09-13 2004-09-10 Inhibitorji matriksnih metaloproteinaz
AT04765231T ATE413384T1 (de) 2003-09-13 2004-09-10 Matrixmetalloproteinaseinhibitoren
PT04765231T PT1663970E (pt) 2003-09-13 2004-09-10 Inibidores da metaloproteinase da matriz
IL173305A IL173305A (en) 2003-09-13 2006-01-23 Matrix metalloproteinase inhibitors, their use in preparation of medicaments, pharmaceutical compositions comprising them and methods of preparation thereof
IS8268A IS2622B (is) 2003-09-13 2006-01-26 Hálfmálmprótínasa hindra mót
NO20060540A NO20060540L (no) 2003-09-13 2006-02-02 Matriks metallproteinase-inhibitorer
ZA200602070A ZA200602070B (en) 2003-09-13 2006-03-10 Matrix metalloproteinase inhibitors
MA28873A MA28039A1 (fr) 2003-09-13 2006-03-14 Inhibiteurs de metalloproteinases matricielles
US12/266,767 US8263602B2 (en) 2003-09-13 2008-11-07 Matrix metalloproteinase inhibitors
RU2008146479/04A RU2008146479A (ru) 2003-09-13 2008-11-26 Ингибиторы матриксных металлопротеиназ
CY20091100090T CY1109400T1 (el) 2003-09-13 2009-01-27 Αναστολεις μεταλλοπρωτεϊνασης μητρας
IS8843A IS8843A (is) 2003-09-13 2009-08-19 Hálfmálmaprótínasa hindra mót
US12/551,892 US8343986B2 (en) 2003-09-13 2009-09-01 Matrix metalloproteinase inhibitors
JP2011132261A JP2011231118A (ja) 2003-09-13 2011-06-14 マトリックスメタロプロテイナーゼの阻害剤
JP2012012663A JP2012107031A (ja) 2003-09-13 2012-01-25 マトリックスメタロプロテイナーゼの阻害剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
GB0321538D0 true GB0321538D0 (en) 2003-10-15

Family

ID=29227079

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0321538.1A Ceased GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds

Country Status (28)

Country Link
US (3) US7601729B2 (enExample)
EP (3) EP1663970B1 (enExample)
JP (3) JP2007505081A (enExample)
KR (3) KR20130079628A (enExample)
CN (1) CN1849306B (enExample)
AT (2) ATE502922T1 (enExample)
AU (1) AU2004272280C1 (enExample)
BR (1) BRPI0413791A (enExample)
CA (1) CA2538315C (enExample)
CY (1) CY1109400T1 (enExample)
DE (2) DE602004031991D1 (enExample)
DK (1) DK1663970T3 (enExample)
ES (2) ES2362954T3 (enExample)
GB (1) GB0321538D0 (enExample)
HR (1) HRP20080668T3 (enExample)
IL (1) IL173305A (enExample)
IS (2) IS2622B (enExample)
MA (1) MA28039A1 (enExample)
MX (1) MXPA06002458A (enExample)
NO (1) NO20060540L (enExample)
NZ (2) NZ573479A (enExample)
PL (1) PL1663970T3 (enExample)
PT (1) PT1663970E (enExample)
RU (2) RU2370488C2 (enExample)
SG (1) SG145685A1 (enExample)
SI (1) SI1663970T1 (enExample)
WO (1) WO2005026120A1 (enExample)
ZA (1) ZA200602070B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
DK1856063T3 (da) * 2005-02-22 2012-03-26 Ranbaxy Lab Ltd 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
BRPI0715231A2 (pt) * 2006-08-22 2013-06-25 Ranbaxy Lab Ltd compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
SG187654A1 (en) 2010-07-30 2013-03-28 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
JP2013540754A (ja) 2010-09-24 2013-11-07 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
US20160045463A1 (en) 2012-11-28 2016-02-18 Universidad De Salamanca Use of metalloprotease inhibitors in the treatment of polycystic liver diseases
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
JP7143334B2 (ja) * 2017-06-13 2022-09-28 エシコン エルエルシー 治癒を制御させる手術用ステープラ

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1995029901A1 (en) * 1994-04-28 1995-11-09 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
HUP9900143A3 (en) * 1995-12-06 2000-04-28 Astra Pharmaceuticals Ltd King Pharmaceutically useful 3-pyridil-compounds
NZ332334A (en) 1996-04-19 2000-06-23 Akzo Nobel Nv Substituted benzylamines and their use for the treatment of depression and other neurologically related disorders
HRP970246B1 (en) * 1996-05-15 2002-04-30 Bayer Ag Substituted oxobutric acids as matrix metalloprotease inhibitors
US5789605A (en) 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US20050065353A1 (en) 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US6242616B1 (en) 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6096904A (en) 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
CA2490819A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2004012663A2 (en) 2002-08-01 2004-02-12 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
DE60330997D1 (de) * 2002-11-19 2010-03-04 Galderma Res & Dev Biaromatische verbindungen die ppar-gamma rezeptoren aktivieren und deren anwendungen in kosmetischen oder pharmazeutischen zusammensetzungen
GB0312654D0 (en) 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
DK1856063T3 (da) 2005-02-22 2012-03-26 Ranbaxy Lab Ltd 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
BRPI0715231A2 (pt) 2006-08-22 2013-06-25 Ranbaxy Lab Ltd compostos, composiÇÕes farmacÊuticas e seus usos, auxiliar quiral e seu uso e processos para preparar um composto

Also Published As

Publication number Publication date
PT1663970E (pt) 2009-01-09
ATE502922T1 (de) 2011-04-15
AU2004272280B2 (en) 2011-04-21
HRP20080668T3 (hr) 2009-02-28
IL173305A (en) 2011-01-31
DE602004017622D1 (de) 2008-12-18
US20100029699A1 (en) 2010-02-04
AU2004272280A1 (en) 2005-03-24
CA2538315C (en) 2014-04-08
CA2538315A1 (en) 2005-03-24
IS8843A (is) 2009-08-19
CY1109400T1 (el) 2014-07-02
US7601729B2 (en) 2009-10-13
ES2362954T3 (es) 2011-07-15
MXPA06002458A (es) 2006-06-20
DK1663970T3 (da) 2009-01-12
JP2011231118A (ja) 2011-11-17
IL173305A0 (en) 2006-06-11
CN1849306B (zh) 2014-01-29
MA28039A1 (fr) 2006-07-03
ZA200602070B (en) 2007-05-30
RU2370488C2 (ru) 2009-10-20
JP2012107031A (ja) 2012-06-07
SG145685A1 (en) 2008-09-29
ATE413384T1 (de) 2008-11-15
NZ545211A (en) 2009-01-31
BRPI0413791A (pt) 2006-11-07
EP2042488A1 (en) 2009-04-01
US8263602B2 (en) 2012-09-11
KR20130079628A (ko) 2013-07-10
AU2004272280C1 (en) 2011-10-27
US8343986B2 (en) 2013-01-01
SI1663970T1 (sl) 2009-04-30
KR20120007566A (ko) 2012-01-20
RU2006106850A (ru) 2007-10-20
KR20060120648A (ko) 2006-11-27
EP1663970B1 (en) 2008-11-05
US20090082377A1 (en) 2009-03-26
NZ573479A (en) 2010-09-30
IS2622B (is) 2010-05-15
PL1663970T3 (pl) 2009-04-30
ES2314436T3 (es) 2009-03-16
DE602004031991D1 (de) 2011-05-05
HK1092141A1 (en) 2007-02-02
US20060293353A1 (en) 2006-12-28
EP2042488B1 (en) 2011-03-23
JP2007505081A (ja) 2007-03-08
CN1849306A (zh) 2006-10-18
RU2008146479A (ru) 2010-06-20
NO20060540L (no) 2006-04-04
WO2005026120A1 (en) 2005-03-24
EP1663970A1 (en) 2006-06-07
EP2295408A1 (en) 2011-03-16
IS8268A (is) 2006-01-26

Similar Documents

Publication Publication Date Title
IS8843A (is) Hálfmálmaprótínasa hindra mót
GB0312654D0 (en) Therapeutically useful compounds
IL154893A0 (en) Aliphatic nitrogen-containing cyclic compounds, methods for the preparation thereof and pharmaceutical compositions containing the same
ATE92928T1 (de) Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen.
HUP0201475A2 (hu) Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
IL85768A0 (en) Benzoxazine derivatives,their preparation and pharmaceutical compositions containing them
DK1010698T3 (da) Hidtil ukendte derivater af 1,2-dithiolan, fremgangsmåde til fremstiling deraf og farmaceutiske sammensætninger indeholdende dem
ATE239021T1 (de) Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
GB1398687A (en) Substituted oxazolidinones and pharmaceutical uses thereof
WO2002074764A3 (en) Piperazine derivatives and their use as 5-ht1b ligands
DE3883434D1 (de) Mitomycinanaloge, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen.
DK1188752T3 (da) Fremgangsmåde til fremstilling af substitueret alkylaminderivat
DK0955310T3 (da) Hidtil ukendte (3,4,7,8,9,10)-hexahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-carboxylsyrederivater, fremgangsmåde til fremstilling af disse og anvendelse af disse til fremstilling af lægemidler
ES464773A1 (es) Procedimiento para la preparacion de 2,9-dioxatriciclo (4,3,1,03,7)decanos.
GB1183442A (enExample)

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)